{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:46:34Z","timestamp":1786549594484,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Albert-Ludwigs-Universit\u00e4t Freiburg im Breisgau"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Infections caused by resistant pathogens represent a global public health challenge. In the current study we aimed to assess the effects on prescription quality and the economic impact of implementing an automated email alert system for last-resort antibiotics, followed by mandatory indication review by infectious diseases (ID) specialists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective single-centre economic and processual evaluation study of orders of last-resort antibiotics at a large tertiary care university hospital (2210 beds) in Germany was performed. Orders of ceftazidime\/avibactam, ceftolozane\/tazobactam, or cefiderocol triggered an indication review by ID specialists with subsequent recommendations to the primary treating physicians. Expected medication costs of continued therapy were compared to projected costs with adherence to ID recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The spectrum of infections for which last-resort antibiotics were prescribed was broad, with respiratory, intraabdominal, skin and soft tissue infections representing\u2009&gt;\u200960% of underlying entities. Dominant pathogens were\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      ,\n                      <jats:italic>Klebsiella<\/jats:italic>\n                      spp. and\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      . ID specialists recommended modifications to the antibiotic regime in almost half of the alerts, including switching (21%), discontinuation (14%) and dosage modifications (7%). Potential cost savings by de-escalation to non-last-resort antibiotics or treatment discontinuation were 65,092\u20ac per year (1,549 \u20ac per initial last-resort antibiotic prescription). Adherence analysis revealed that further improvement appears feasible, potentially through structured follow-up ID consultations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Implementation of automated last-resort antibiotic alerts, followed by an indication review by ID specialists, proved to be a valuable tool with respect to prescription quality and economic benefits. Generalisability of this approach should be investigated in non-tertiary care settings. Moreover, future studies should address potential effects on clinical outcomes and antimicrobial resistance patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02894-9","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:50:05Z","timestamp":1786546205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of automated alerts for last-resort antibiotics with indication review by infectious diseases specialists: impact on antibiotic prescription quality and costs"],"prefix":"10.1007","author":[{"given":"Siegbert","family":"Rieg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Kainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Strub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hornuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Kaech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Hug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6236-6597","authenticated-orcid":false,"given":"Gesche","family":"F\u00f6rst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"10325","key":"2894_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"2894_CR2","unstructured":"WHO Antimicrobial Resistance Division. Global action plan on antimicrobial resistance. In. Geneva: World Health Organization. 2015 [cited 2026 Jun 25]. p. 45. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241509763"},{"key":"2894_CR3","doi-asserted-by":"publisher","unstructured":"OECD. Antimicrobial Resistance Tackling the Burden in the European Union. Tackling the Burden in the European Union [Internet]. 2019 [cited 2025 Nov 11]. Available from: https:\/\/www.oecd.org\/en\/publications\/antimicrobial-resistance-tackling-the-burden-in-the-european-union_33cbfc1c-en.htmlhttps:\/\/doi.org\/10.1787\/33cbfc1c-en","DOI":"10.1787\/33cbfc1c-en"},{"issue":"6","key":"2894_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00103-025-04061-1","volume":"68","author":"C Willy","year":"2025","unstructured":"Willy C, Br\u00f6cker F. Gesundheits\u00f6konomische Bedeutung antimikrobieller Resistenzen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2025;68(6):584\u201392. https:\/\/doi.org\/10.1007\/s00103-025-04061-1.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"issue":"5","key":"2894_CR5","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1007\/s15010-025-02507-x","volume":"53","author":"H Stocker","year":"2025","unstructured":"Stocker H, Kron F, Hartmann P, De With K, Addo M, Vehreschild M, et al. Caseload, clinical spectrum and economic burden of infectious diseases in patients discharged from hospitals in Germany. Infection. 2025;53(5):1863\u201373. https:\/\/doi.org\/10.1007\/s15010-025-02507-x.","journal-title":"Infection"},{"key":"2894_CR6","unstructured":"Bundesministerium der Justiz und f\u00fcr Verbraucherschutz. Gesetz f\u00fcr fairen Wettbewerb in der gesetzlichen Krankenversicherung SGB V \u00a7 35a. Bundesgesetzblatt [Internet]. 2020. Available from: https:\/\/www.bgbl.de\/xaver\/bgbl\/start.xav?startbk=Bundesanzeiger_BGBl&start=%2F%2F%2A%5B%40attr_id=%27bgbl120s0604.pdf%27%5D#\/switch\/tocPane?_ts=1782400582214"},{"issue":"5","key":"2894_CR7","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.57187\/s.4217","volume":"155","author":"J Huser","year":"2025","unstructured":"Huser J, D\u00f6rr T, Berger A, Kohler P, Kuster SP. Economic evaluations of antibiotic stewardship programmes 2015\u20132024: a systematic review. Swiss Med Wkly. 2025;155(5):4217. https:\/\/doi.org\/10.57187\/s.4217.","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"2894_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jhin.2019.03.002","volume":"102","author":"C Huebner","year":"2019","unstructured":"Huebner C, Flessa S, Huebner NO. The economic impact of antimicrobial stewardship programmes in hospitals: a systematic literature review. J Hosp Infect. 2019;102(4):369\u201376. https:\/\/doi.org\/10.1016\/j.jhin.2019.03.002.","journal-title":"J Hosp Infect"},{"key":"2894_CR9","doi-asserted-by":"publisher","unstructured":"Krishnamoorthy Y, Govindan D, Karunakaran M, Parveen M, Manohar A, Al-Tawfiq JA. Global impact of antimicrobial stewardship programs in Healthcare: An umbrella review of effectiveness, cost-efficiency, and implementation strategies. J Infect Chemother. 2025;31(8). https:\/\/doi.org\/10.1016\/j.jiac.2025.102753.","DOI":"10.1016\/j.jiac.2025.102753"},{"issue":"9","key":"2894_CR10","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1093\/jac\/dkac185","volume":"77","author":"BL Wubishet","year":"2022","unstructured":"Wubishet BL, Merlo G, Ghahreman-Falconer N, Hall L, Comans T. Economic evaluation of antimicrobial stewardship in primary care: a systematic review and quality assessment. J Antimicrob Chemother. 2022;77(9):2373\u201388. https:\/\/doi.org\/10.1093\/jac\/dkac185.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2894_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13756-019-0471-0","volume":"8","author":"D Nathwani","year":"2019","unstructured":"Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrob Resist Infect Control. 2019;8(1):35. https:\/\/doi.org\/10.1186\/s13756-019-0471-0.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"8","key":"2894_CR12","doi-asserted-by":"publisher","first-page":"e00307","DOI":"10.1128\/AAC.00307-20","volume":"64","author":"JT Bork","year":"2020","unstructured":"Bork JT, Claeys KC, Heil EL, Banoub M, Leekha S, Sorkin JD, et al. A Propensity Score Matched Study of the Positive Impact of Infectious Diseases Consultation on Antimicrobial Appropriateness in Hospitalized Patients with Antimicrobial Stewardship Oversight. Antimicrob Agents Chemother. 2020;64(8):e00307\u201320. https:\/\/doi.org\/10.1128\/AAC.00307-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2894_CR13","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/cid\/ciaa388","volume":"72","author":"DJ Livorsi","year":"2021","unstructured":"Livorsi DJ, Nair R, Lund BC, Alexander B, Beck BF, Goto M, et al. Antibiotic Stewardship Implementation and Antibiotic Use at Hospitals With and Without On-site Infectious Disease Specialists. Clin Infect Dis. 2021;72(10):1810\u20137. https:\/\/doi.org\/10.1093\/cid\/ciaa388.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2894_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s15010-016-0883-1","volume":"44","author":"S Rieg","year":"2016","unstructured":"Rieg S, K\u00fcpper MF. Infectious diseases consultations can make the difference: a brief review and a plea for more infectious diseases specialists in Germany. Infection. 2016;44(2):159\u201366. https:\/\/doi.org\/10.1007\/s15010-016-0883-1.","journal-title":"Infection"},{"issue":"9","key":"2894_CR15","doi-asserted-by":"publisher","first-page":"e2234186","DOI":"10.1001\/jamanetworkopen.2022.34186","volume":"5","author":"EE Pliakos","year":"2022","unstructured":"Pliakos EE, Ziakas PD, Mylonakis E. Economic Analysis of Infectious Disease Consultation for Staphylococcus aureus Bacteremia Among Hospitalized Patients. JAMA Netw Open. 2022;5(9):e2234186. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.34186.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2894_CR16","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S1473-3099(19)30405-0","volume":"19","author":"C Mejia-Chew","year":"2019","unstructured":"Mejia-Chew C, O\u2019Halloran JA, Olsen MA, Stwalley D, Kronen R, Lin C, et al. Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. Lancet Infect Dis. 2019;19(12):1336\u201344. https:\/\/doi.org\/10.1016\/S1473-3099(19)30405-0.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2894_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/cid\/ciae282","volume":"79","author":"SWX Ong","year":"2024","unstructured":"Ong SWX, Luo J, Fridmann D, Lee S, Johnstone J, Schwartz K, et al. Association Between Infectious Diseases Consultation and Mortality in Hospitalized Patients With Gram-negative Bloodstream Infection: A Retrospective Population-wide Cohort Study. Clin Infect Dis. 2024;79(4):855\u201363. https:\/\/doi.org\/10.1093\/cid\/ciae282.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2894_CR18","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/cid\/ciu522","volume":"59","author":"B Hamandi","year":"2014","unstructured":"Hamandi B, Husain S, Humar A, Papadimitropoulos EA. Impact of Infectious Disease Consultation on the Clinical and Economic Outcomes of Solid Organ Transplant Recipients Admitted for Infectious Complications. Clin Infect Dis. 2014;59(8):1074\u201382. https:\/\/doi.org\/10.1093\/cid\/ciu522.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2894_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jmii.2013.01.010","volume":"47","author":"CP Shih","year":"2014","unstructured":"Shih CP, Lin YC, Chan YY, Hsu KH. Employing infectious disease physicians affects clinical and economic outcomes in regional hospitals: Evidence from a population-based study. J Microbiol Immunol Infect. 2014;47(4):297\u2013303. https:\/\/doi.org\/10.1016\/j.jmii.2013.01.010.","journal-title":"J Microbiol Immunol Infect"},{"key":"2894_CR20","unstructured":"De With K, Wilke K, Kern WV, Strau\u00df R, Kramme E, Friedrichs A et al. S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus [Internet]. AWMF; 2018. Available from: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/092-001"},{"issue":"2","key":"2894_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inf"},{"issue":"10","key":"2894_CR22","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/jac\/dkx244","volume":"72","author":"G F\u00f6rst","year":"2017","unstructured":"F\u00f6rst G, De With K, Weber N, Borde J, Querbach C, Kleideiter J, et al. Validation of adapted daily dose definitions for hospital antibacterial drug use evaluation: a multicentre study. J Antimicrob Chemother. 2017;72(10):2931\u20137. https:\/\/doi.org\/10.1093\/jac\/dkx244.","journal-title":"J Antimicrob Chemother"},{"key":"2894_CR23","unstructured":"ADKA-if-DGI. Antiinfektiva-Surveillance Projekt [Internet]. 2025. Wirkstoffliste RDD 2025. Available from: https:\/\/antiinfektiva-surveillance.de\/projekt\/"},{"key":"2894_CR24","unstructured":"G\u00fcnther J, Schmiedl S, Zawinell A. Amtliche Fassung des ATC-Index mit DDD-Angaben f\u00fcr Deutschland im Jahr 2025. Bundesinstitut F\u00fcr Arzneim Med [Internet]. 2025. Available from: https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Kodiersysteme\/ATC\/atc-ddd-amtlich-2025.pdf?__blob=publicationFile"},{"issue":"3","key":"2894_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"2894_CR26","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.3390\/healthcare10122546","volume":"10","author":"J Jeck","year":"2022","unstructured":"Jeck J, Wingen-Heimann SM, Jakobs F, Franz J, Baltin CT, Kron A, et al. Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany. Healthcare. 2022;10(12):2546. https:\/\/doi.org\/10.3390\/healthcare10122546.","journal-title":"Healthcare"},{"key":"2894_CR27","doi-asserted-by":"publisher","unstructured":"Robert Koch Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2023. https:\/\/doi.org\/10.25646\/13043","DOI":"10.25646\/13043"},{"issue":"11","key":"2894_CR28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/10766294251384459","volume":"31","author":"J Sommer","year":"2025","unstructured":"Sommer J, Esse J, Held J, Voigtl\u00e4nder S, Bogdan C, Valenza G. Clinical Epidemiology and Antimicrobial Susceptibility of Carbapenemase-Producing Enterobacterales from a German University Hospital During a 5-Year Period. Microb Drug Resist. 2025;31(11):374\u20139. https:\/\/doi.org\/10.1177\/10766294251384459.","journal-title":"Microb Drug Resist"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02894-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:50:08Z","timestamp":1786546208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02894-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":28,"alternative-id":["2894"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02894-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present work did not require formal ethical approval because it involved only the analysis of internal process data that support the implementation of the Federal Ministry of Health\u2019s guidelines. No additional patient-related or personally identifiable health information was collected, stored, or processed. The study and the associated intervention were solely intended to evaluate and facilitate the correct application of existing regulations, and all activities were conducted in accordance with applicable data-protection and research-ethics standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}